Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Public Health, Vientiane, Laos | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia. The study aims at providing evidence on effective doses and safety of moxidectin in adults against infection with S. stercoralis in Laos (trial 2a) and efficacy and safety of moxidectin compared to ivermectin in adults against infection with S. stercoralis in Laos and Cambodia (trial 2b). The efficacy of the treatment will be assessed by collecting three stool samples once pre-treatment and once 21 days post-treatment. The stool samples will be analyzed by a quantitative Baermann assay.
This is a phase 2a single-blinded and a phase 2b double-blinded randomized clinical trial, which aims to determine efficacy and safety of (2a) seven ascending oral moxidectin dosages in 210 adults infected with S. stercoralis, namely placebo, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg in Lao and (2b) the recommended dose moxidectin (i.e. the most promising dosage identified in trial A; between 2-12 mg) in comparison to the standard treatment dose of ivermectin (200 µg/kg) in 350 adults infected with S. stercoralis in Lao and Cambodia. Embedded in the trial is a pharmacokinetic/-dynamic study with the goal to measure moxidectin disposition in adults and to determine population pharmacokinetic (PK) parameters of the optimal dose of moxidectin in the treatment of S. stercoralis.
The primary objective is to determine the dose-response of moxidectin based on cure rates (CR) against S. stercoralis and to quantify the efficacy of the recommended dose to the standard treatment (ivermectin) in adults.
The secondary objectives of the trial are: Evaluation of the safety and tolerability of the dose-dependent treatment regimes, evaluation of the safety and tolerability of moxidectin compared to ivermectin, comparison of the larvae reduction rate (LRR) of the different treatment regimens against S. stercoralis (trial 2a,b), determination of an exposure- (including Cmax, area under curve (AUC) and tmax) -response correlation of moxidectin in adults, comparison of the exposure-response of moxidectin using venous and capillary blood, evaluation of the cure rate of the different moxidectin treatment regimens against co-infection and the determination of the population PK parameters of the optimal dose of moxidectin in the treatment of S. stercoralis.
After obtaining informed consent from each individual, the medical history of the participants will be assessed with a standardized questionnaire, in addition to a clinical examination carried out by the study physician before treatment. Enrollment will be based on collection and analysis by a quantitative Baermann method (in duplicates) of three stool samples. Randomization of participants into the different treatment arms will be stratified according to intensity of infection. The adults will also be interviewed before treatment, 3 and 24 hours as well as 21 days after treatment about the occurrence of adverse events (AE). The efficacy of the treatment will be determined 21 days post-treatment by collecting another three stool samples. All stool samples will be examined with duplicate Baermann assays recorded quantitatively. Co-infection with T. trichiura, A. lumbricoides and hookworm infection will be identified using duplicate Kato-Katz thick smears on stool samples.
A subsample of adults will further be sampled using finger pricking for micro sampling at 0, 2, 4, 8, 24, and 72 hours, 7 and 21 days post treatment to evaluate pharmacokinetic parameters (trial phase 2a) and at defined time windows, that are based on the PK model earned from trial 2a (trial phase 2b). For validation of the analytical method the subsample of one study arm (8 mg, trial phase 2a) will undergo venous blood sampling in addition to finger pricking.
An available case analysis (full analysis set according to the intention to treat principle) will be performed, including all subjects with primary end point data. Supplementary, a per-protocol analysis will be conducted. CRs will be calculated as the percentage of larvae-positive subjects at baseline who become larvae-negative after treatment. Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))*100) Geometric and arithmetic mean larvae counts will be calculated for the different treatment arms before and after treatment to assess the corresponding LRRs. Bootstrap resampling method with 2,000 replicates will be used to calculate 95% confidence intervals (CIs) for LRRs. Emax models using the dose finding package of the statistical software environment R will be implemented to predict the dose-response curves in terms of CRs and LRRs.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Phase 2a - Arm A | Experimental | 2 mg Moxidectin at day 0 administered orally |
|
| Phase 2a - Arm B | Experimental | 4 mg Moxidectin at day 0 administered orally |
|
| Phase 2a - Arm C | Experimental | 6 mg Moxidectin at day 0 administered orally |
|
| Phase 2a - Arm D | Experimental | 8 mg Moxidectin at day 0 administered orally |
|
| Phase 2a - Arm E | Experimental | 10 mg Moxidectin at day 0 administered orally |
|
| Phase 2a - Arm F | Experimental | 12 mg Moxidectin at day 0 administered orally |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Moxidectin | Drug | Monotherapy, oral administration, single dose, fixed dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Observed Cure Rate Against Strongyloides Stercoralis | The conversion from being larvae positive pre-treatment to larvae negative post-treatment, or cure rate (CR). | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Observed Larvae-reduction Rate (LRR) Against Strongyloides Stercoralis | Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))*100) | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jennifer Keiser, Prof. Dr. | Swiss TPH | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institute of Public Health | Vientiane | Laos |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37949090 | Derived | Sprecher VP, Hofmann D, Savathdy V, Xayavong P, Norkhankhame C, Huy R, Khieu V, Sayasone S, Hattendorf J, Keiser J. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial. Lancet Infect Dis. 2024 Feb;24(2):196-205. doi: 10.1016/S1473-3099(23)00507-8. Epub 2023 Nov 7. | |
| 34296417 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Phase 2a - Arm A (Moxidectin 2 mg) | 2 mg Moxidectin at day 0 administered orally |
| FG001 | Phase 2a - Arm B (Moxidectin 4 mg) | 4 mg Moxidectin at day 0 administered orally |
| FG002 | Phase 2a - Arm C (Moxidectin 6 mg) | 6 mg Moxidectin at day 0 administered orally |
| FG003 | Phase 2a - Arm D (Moxidectin 8 mg) | 8 mg Moxidectin at day 0 administered orally |
| FG004 | Phase 2a - Arm E (Moxidectin 10 mg) | 10 mg Moxidectin at day 0 administered orally |
| FG005 | Phase 2a - Arm F (Moxidectin 12 mg) | 12 mg Moxidectin at day 0 administered orally |
| FG006 | Phase 2a - Arm G (Placebo) | matching Placebo tablet(s) at day 0 administered orally |
| FG007 | Phase 2b - Arm A (Moxidectin) | 8 mg moxidectin (i.e. the most promising dosage identified in trial A; between 2-12 mg) at day 0 administered orally + Ivermectin placebo dose, corresponding to Phase 2b - Arm B |
| FG008 | Phase 2b - Arm B (Ivermectin) | 200 µg/kg ivermectin at day 0 administered orally + Moxidectin placebo dose, corresponding to Phase 2b - Arm A |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2a |
| |||||||||||||
| Phase 2b |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Phase 2a - Arm A (Moxidectin 2 mg) | 2 mg Moxidectin at day 0 administered orally |
| BG001 | Phase 2a - Arm B (Moxidectin 4 mg) | 4 mg Moxidectin at day 0 administered orally |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | In phase 2a, the analysis population is the intention-to-treat population, excluding participants lost to follow-up. In phase 2b, the analysis population includes all randomized participants. |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Observed Cure Rate Against Strongyloides Stercoralis | The conversion from being larvae positive pre-treatment to larvae negative post-treatment, or cure rate (CR). | Posted | Number | 95% Confidence Interval | percentage of participants | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
|
21-28 days (phase 2a) / 14-21 days (phase 2b)
Participants were monitored at the site for 3 hours following treatment. In addition, participants were interviewed at 2-3 and 24 hours after treatment and retrospectively at 21-28 days (phase 2a) or 14-21 days (phase 2b) about the occurrence of adverse events.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Phase 2a - Arm A (Moxidectin 2 mg) | 2 mg Moxidectin at day 0 administered orally |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal pain | Gastrointestinal disorders | CTCAE (5.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Prof Dr Jennifer Keiser | Swiss Tropical and Public Health Institute | +41 61 284 82 18 | jennifer.keiser@swisstph.ch |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jul 1, 2020 | Apr 22, 2023 | Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| C027837 | moxidectin |
| D007559 | Ivermectin |
| ID | Term |
|---|---|
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
Not provided
Not provided
Phase 2a: Parallel study with 7 treatment arms (including a placebo arm) Phase 2b: Parallel study with 2 treatment arms
Not provided
Not provided
Phase 2a: single-blinded (participant and lab technician) Phase 2b: double-blinded (participant, Care Provider) PK sub-studies are single-blinded (participant)
| Phase 2a - Arm G | Placebo Comparator | matching Placebo tablet(s) at day 0 administered orally |
|
| Phase 2b - Arm A | Experimental | the recommended dose moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally + Ivermectin placebo, corresponding to Phase 2b - Arm B |
|
| Phase 2b - Arm B | Active Comparator | 200 µg/kg ivermectin at day 0 administered orally + Moxidectin placebo, corresponding to Phase 2b - Arm A |
|
| Ivermectin | Drug | Monotherapy, oral administration, single dose, weight dependent |
|
| Placebo oral tablet | Drug | Monotherapy, oral administration, single dose, matching number of tablets |
|
| Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Ascaris Lumbricoides | CRs will be calculated for Ascaris lumbricoides infections as described in primary outcome. | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
| Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Trichuris Trichiura | CRs will be calculated for Trichuris trichiura infections as described in primary outcome. | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
| Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Hookworm | CRs will be calculated for Hookworm infections as described in primary outcome. | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
| Number of Participants Reporting Adverse Events | Subjects will be kept for observation for at least 3 hours following treatment for any acute AEs. If there is any abnormal finding, the local study physician will perform a full clinical, physical and biochemical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. In addition patients will also be interviewed 2-3 and 24 hours and again 3-4 (phase 2a) or 2-3 (phase 2b) weeks after treatment about the occurrence of AEs. A standardized symptom questionnaire is used, that includes the recording of headache, abdominal pain, itching, nausea, vomiting, diarrhea, allergic reaction as well as any further mentioned event by the participant. | 2-3 hours, 24 hours, and retrospectively 21-28 days (phase 2a) or 14-21 days (phase 2b Arm A and Arm B) after treatment. |
| Maximum Concentration (Cmax) of Moxidectin in Adults | Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model. | 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment. |
| Time to Reach Cmax (Tmax) of Moxidectin in Adults | Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model. | 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment. |
| Area Under the Curve (AUC) of Moxidectin in Adults | Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model. | 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment. |
| Elimination Half Life (T1/2) of Moxidectin in Adults | Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model. | 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment. |
| Derived |
| Smit C, Hofmann D, Sayasone S, Keiser J, Pfister M. Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen. Clin Pharmacokinet. 2022 Jan;61(1):123-132. doi: 10.1007/s40262-021-01048-4. Epub 2021 Jul 23. |
| 33798487 | Derived | Hofmann D, Sayasone S, Sengngam K, Chongvilay B, Hattendorf J, Keiser J. Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial. Lancet Infect Dis. 2021 Aug;21(8):1151-1160. doi: 10.1016/S1473-3099(20)30691-5. Epub 2021 Mar 30. |
| COMPLETED |
|
| NOT COMPLETED |
|
| BG002 | Phase 2a - Arm C (Moxidectin 6 mg) | 6 mg Moxidectin at day 0 administered orally |
| BG003 | Phase 2a - Arm D (Moxidectin 8 mg) | 8 mg Moxidectin at day 0 administered orally |
| BG004 | Phase 2a - Arm E (Moxidectin 10 mg) | 10 mg Moxidectin at day 0 administered orally |
| BG005 | Phase 2a - Arm F (Moxidectin 12 mg) | 12 mg Moxidectin at day 0 administered orally |
| BG006 | Phase 2a - Arm G (Placebo) | matching Placebo tablet(s) at day 0 administered orally |
| BG007 | Phase 2b - Arm A (Moxidectin) | 8 mg moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally + Ivermectin placebo dose, corresponding to Phase 2b - Arm B |
| BG008 | Phase 2b - Arm B (Ivermectin) | 200 µg/kg ivermectin at day 0 administered orally + Moxidectin placebo dose, corresponding to Phase 2b - Arm A |
| BG009 | Total | Total of all reporting groups |
| Mean |
| Standard Deviation |
| years |
|
| Sex: Female, Male | In phase 2a, the analysis population is the intention-to-treat population, excluding participants lost to follow-up. In phase 2b, the analysis population includes all randomized participants. | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Strongyloides stercoralis infection intensity | In phase 2a, the analysis population is the intention-to-treat population, excluding participants lost to follow-up. In phase 2b, the analysis population includes all randomized participants. | Count of Participants | Participants |
|
6 mg Moxidectin at day 0 administered orally |
| OG003 | Phase 2a - Arm D (Moxidectin 8 mg) | 8 mg Moxidectin at day 0 administered orally |
| OG004 | Phase 2a - Arm E (Moxidectin 10 mg) | 10 mg Moxidectin at day 0 administered orally |
| OG005 | Phase 2a - Arm F (Moxidectin 12 mg) | 12 mg Moxidectin at day 0 administered orally |
| OG006 | Phase 2a - Arm G (Placebo) | matching Placebo tablet(s) at day 0 administered orally |
| OG007 | Phase 2b - Arm A (Moxidectin) | 8 mg moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally + Ivermectin placebo dose, corresponding to Phase 2b - Arm B |
| OG008 | Phase 2b - Arm B (Ivermectin) | 200 µg/kg ivermectin at day 0 administered orally + Moxidectin placebo dose, corresponding to Phase 2b - Arm A |
|
|
| Secondary | Observed Larvae-reduction Rate (LRR) Against Strongyloides Stercoralis | Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))*100) | Posted | Geometric Mean | 95% Confidence Interval | percent change | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
|
|
|
| Secondary | Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Ascaris Lumbricoides | CRs will be calculated for Ascaris lumbricoides infections as described in primary outcome. | Participants co-infected with A. lumbricoides | Posted | Number | 95% Confidence Interval | percentage of participants | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
|
|
|
| Secondary | Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Trichuris Trichiura | CRs will be calculated for Trichuris trichiura infections as described in primary outcome. | Number of Participants co-infected with T. trichiura | Posted | Number | percentage of participants | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
|
|
|
| Secondary | Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Hookworm | CRs will be calculated for Hookworm infections as described in primary outcome. | Participants co-infected with Hookworm | Posted | Number | percentage of participants | Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment |
|
|
|
| Secondary | Number of Participants Reporting Adverse Events | Subjects will be kept for observation for at least 3 hours following treatment for any acute AEs. If there is any abnormal finding, the local study physician will perform a full clinical, physical and biochemical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. In addition patients will also be interviewed 2-3 and 24 hours and again 3-4 (phase 2a) or 2-3 (phase 2b) weeks after treatment about the occurrence of AEs. A standardized symptom questionnaire is used, that includes the recording of headache, abdominal pain, itching, nausea, vomiting, diarrhea, allergic reaction as well as any further mentioned event by the participant. | Phase 2a: Analysis population N=209 at all time points. Phase 2b: Analysis population at 2-3 hours after drug administration: N=394. Analysis population at 24 hours after drug administration: N=394. Analysis population at 14-21 days after drug administration: N=381. | Posted | Count of Participants | Participants | 2-3 hours, 24 hours, and retrospectively 21-28 days (phase 2a) or 14-21 days (phase 2b Arm A and Arm B) after treatment. |
|
|
|
| Secondary | Maximum Concentration (Cmax) of Moxidectin in Adults | Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model. | Data were only collected in phase 2a - Arm D (Moxidectin 8 mg). | Posted | Median | Inter-Quartile Range | ng/mL | 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment. |
|
|
|
| Secondary | Time to Reach Cmax (Tmax) of Moxidectin in Adults | Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model. | Data were only collected in phase 2a - Arm D (Moxidectin 8 mg). | Posted | Median | Inter-Quartile Range | hours | 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment. |
|
|
|
| Secondary | Area Under the Curve (AUC) of Moxidectin in Adults | Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model. | Data were only collected in phase 2a - Arm D (Moxidectin 8 mg). | Posted | Median | Inter-Quartile Range | ng/mL*h | 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment. |
|
|
|
| Secondary | Elimination Half Life (T1/2) of Moxidectin in Adults | Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model. | Data were only collected in phase 2a - Arm D (Moxidectin 8 mg). | Posted | Median | Inter-Quartile Range | hours | 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment. |
|
|
|
| 0 |
| 31 |
| 0 |
| 31 |
| 3 |
| 31 |
| EG001 | Phase 2a - Arm B (Moxidectin 4 mg) | 4 mg Moxidectin at day 0 administered orally | 0 | 33 | 0 | 33 | 6 | 33 |
| EG002 | Phase 2a - Arm C (Moxidectin 6 mg) | 6 mg Moxidectin at day 0 administered orally | 0 | 33 | 0 | 33 | 3 | 33 |
| EG003 | Phase 2a - Arm D (Moxidectin 8 mg) | 8 mg Moxidectin at day 0 administered orally | 0 | 32 | 0 | 32 | 5 | 32 |
| EG004 | Phase 2a - Arm E (Moxidectin 10 mg) | 10 mg Moxidectin at day 0 administered orally | 0 | 32 | 0 | 32 | 7 | 32 |
| EG005 | Phase 2a - Arm F (Moxidectin 12 mg) | 12 mg Moxidectin at day 0 administered orally | 0 | 30 | 0 | 30 | 1 | 30 |
| EG006 | Phase 2a - Arm G (Placebo) | matching Placebo tablet(s) at day 0 administered orally | 0 | 32 | 0 | 32 | 12 | 32 |
| EG007 | Phase 2b - Arm A (Moxidectin) | 8 mg moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally + Ivermectin placebo dose, corresponding to Phase 2b - Arm B | 0 | 197 | 0 | 197 | 59 | 197 |
| EG008 | Phase 2b - Arm B (Ivermectin) | 200 µg/kg ivermectin at day 0 administered orally + Moxidectin placebo dose, corresponding to Phase 2b - Arm A | 0 | 197 | 0 | 197 | 60 | 197 |
| Diarrhea | Gastrointestinal disorders | CTCAE (5.0) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | CTCAE (5.0) | Systematic Assessment |
|
| Headache | General disorders | CTCAE (5.0) | Systematic Assessment |
|
| Nausea | General disorders | CTCAE (5.0) | Systematic Assessment |
|
| Allergic reaction | General disorders | CTCAE (5.0) | Systematic Assessment |
|
| Itching | Skin and subcutaneous tissue disorders | CTCAE (5.0) | Systematic Assessment |
|
Not provided
Not provided
Not provided
| Male |
|
| Moderate |
|
| Heavy |
|
|
| 2-3 hours: Abdominal pain |
|
|
| 2-3 hours: Itching |
|
|
| 2-3 hours: Nausea |
|
|
| 2-3 hours: Vomiting |
|
|
| 2-3 hours: Diarrhea |
|
|
| 2-3 hours: Allergic reaction |
|
|
| 24 hours: Headache |
|
|
| 24 hours: Abdominal pain |
|
|
| 24 hours: Itching |
|
|
| 24 hours: Nausea |
|
|
| 24 hours: Vomiting |
|
|
| 24 hours: Diarrhea |
|
|
| 24 hours: Allergic reaction |
|
|
| 21-28/14-21 days: Headache |
|
|
| 21-28/14-21 days: Abdominal pain |
|
|
| 21-28/14-21 days: Itching |
|
|
| 21-28/14-21 days: Nausea |
|
|
| 21-28/14-21 days: Vomiting |
|
|
| 21-28/14-21 days: Diarrhea |
|
|
| 21-28/14-21 days: Allergic reaction |
|
|